Researchers from Harvard Medical School, Yale University and University of Leiden have uncovered two new potential biomarkers of dysregulated glucose metabolism in Alzheimer’s disease (AD). Glucose hypometabolism is consistently observed in AD but the molecular changes behind this are unclear. Findings from recent research have indicated dysregulation of glycolysis markers in AD cerebrospinal fluid (CSF) and tissue.
Researchers from Washington University in St. Louis reported data validating microtubule-binding region (MTBR) of tau containing the residue 243 (MTBR-tau243) as a new cerebrospinal fluid (CSF) biomarker specific for insoluble tau aggregates in Alzheimer’s disease (AD).
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. presented the discovery and preclinical evaluation of novel EGFR(T790M/C797S) inhibitors for the treatment of mutant non-small-cell lung cancer (NSCLC).
Bacteria cells are masters of adaptation and evolution, and by better understanding how they adapt and evolve, researchers hope to develop better drugs to fight microbial resistance, which is increasingly becoming a global public health threat. Researchers from the antimicrobial resistance interdisciplinary research group at the Singapore-MIT Alliance for Research and Technology (SMART) sought to understand the mechanisms bacteria use to adapt against stressors, and they discovered a new stress signaling system that sheds light on a new mechanism of antimicrobial resistance.
Avoidance of graft-vs.-host disease (GVHD) after a hematopoietic stem cell transplant could depend on certain members of the microbiome. According to a study led by scientists at the Fred Hutchinson Cancer Center (FHCC), while some species of intestinal bacteria repressed the expression of the major histocompatibility complex II (MHC-II), others induced it and triggered the immune response that produces GVHD.
Research at Insilico Medicine Inc. has led to the development of CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disorders and inflammation.
Galectin-3 (LGALS3) and/or galectin-9 (LGALS9) inhibitors are reported in a Galecto Biotech AB patent as potentially useful for the treatment of cancer, autoimmune disease, fibrosis, cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among others.
A Chiesi Farmaceutici SpA patent details cyclohexane acid derivatives acting as lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists and thus reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Jeil Pharmaceutical Co. Ltd. has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, ulcerative colitis, rheumatoid arthritis, autoimmune disease, cardiovascular disorders and dermatological and inflammatory disorders and neurological disorders, among others.
RSS
